IRDHIGH SIGNALFINANCIAL10-K

IRD completed a major equity financing that increased outstanding shares by 56% while dramatically improving the balance sheet, though operational cash burn worsened significantly.

The company raised substantial capital (cash increased $14.8M to $45.1M) through a dilutive equity offering that increased shares outstanding from 45.5M to 71.1M, representing major dilution for existing shareholders. While this financing strengthened the balance sheet and removed previous acquisition-related risks, the 38% worsening in operating cash flow to -$35.3M signals accelerating cash burn despite reduced R&D spending.

Comparing 2026-03-12 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

IRD's financial profile shows a company that completed a significant capital raise while experiencing mixed operational results. The balance sheet strengthened substantially with cash increasing 49% to $45.1M and total assets growing 36%, funded by equity that boosted stockholders' equity 128% but diluted existing shareholders significantly. However, operational performance deteriorated with operating cash flow worsening 38% to -$35.3M despite R&D expenses falling 58%, suggesting increased spending in other areas and highlighting the company's continued cash consumption despite the recent financing.

FINANCIAL STATEMENT CHANGES
Total Liabilities
Balance Sheet
+208.9%
$11.3M$34.9M

Liabilities grew 208.9% — significant increase in debt or obligations, assess impact on financial flexibility.

Stockholders Equity
Balance Sheet
+128.3%
$6.7M$15.3M

Equity base grew 128.3% — retained earnings accumulation or equity issuance strengthening the balance sheet.

R&D Expense
P&L
-58.2%
$13.1M$5.5M

R&D spending cut 58.2% — could signal cost discipline or concerning reduction in innovation investment.

Cash & Equivalents
Balance Sheet
+48.7%
$30.3M$45.1M

Cash position surged 48.7% — strong cash generation or capital raise providing significant financial cushion.

Accounts Receivable
Balance Sheet
-44%
$3.6M$2.0M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Operating Income
P&L
+37.8%
-$62.1M-$38.6M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Operating Cash Flow
Cash Flow
-37.8%
-$25.6M-$35.3M

Operating cash flow fell 37.8% — earnings quality concerns; investigate working capital changes and non-cash items.

Current Assets
Balance Sheet
+36.7%
$36.6M$50.0M

Current assets grew 36.7% — improving short-term liquidity or inventory/receivables build.

Total Assets
Balance Sheet
+36.3%
$36.9M$50.2M

Asset base grew 36.3% — expansion through organic growth, acquisitions, or capital deployment.

Current Liabilities
Balance Sheet
-31.1%
$11.3M$7.8M

Current liabilities reduced — improved short-term financial position and working capital health.

LANGUAGE CHANGES
NEW — 2026-03-12
PRIOR — 2025-03-31
ADDED
As of March 5, 2026, there were 71,149,045 shares of the registrant s common stock outstanding.
Our planned clinical trials may face substantial delays, result in failure, or provide inconclusive or adverse results that may not satisfy U.S.
Food and Drug Administration ( FDA ) requirements to further develop our therapeutic products.
Our ability to utilize our common stock to finance future capital needs, or for other purposes, is limited by our authorized shares available for issuance.
Risks Related to Government Regulation Instability and operational disruptions at government agencies, such as the FDA, may adversely impact our development and commercialization plans by causing delays and requiring the use of additional, unforeseen resources to obtain regulatory approval for trials or products in our pipeline.
+7 more — sign up free →
REMOVED
As of March 27, 2025, there were 45,483,823 shares of the registrant s common stock outstanding.
Risks Related to the Opus Acquisition Failure to successfully integrate our businesses with Former Opus (as defined below) could have a material adverse effect on our business, financial condition and results of operations.
The Opus Acquisition (as defined below) significantly expanded our product pipeline and business operations and shifted our business strategies, which may not improve the value of our common stock.
Our planned clinical trials may face substantial delays, result in failure, or provide inconclusive or adverse results that may not satisfy FDA requirements to further develop our therapeutic products.
Risks Related to Government Regulation We operate in a highly regulated industry and face many challenges adapting to sudden changes in legislative reform or the regulatory environment, which affects our pipeline stability and could impair our ability to compete in international markets.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →